David Dean, Cardiome Investor Relations, (604) 677-6905 ext. 311 or Toll Free: 1-800-330-9928, Email: ddean@cardiome.comCopyright CNW Group 2015
Cardiome Reports Third Quarter 2015 Financial Results
View original source (CNW)Correvio Pharma Corp on 6ix
Earlier from Correvio Pharma
- Cardiome to Hold Third Quarter 2015 Financial Results Conference Call on November 13
- Cardiome announces addition of Robert James Meyer, M.D. to board of directors
- Cardiome to Present at the 17th Annual Rodman & Renshaw Global Investment Conference
- Cardiome Expands Partnership with Eddingpharm to Commercialize AGGRASTAT in China
- United Kingdom Department of Health Sets BRINAVESS Pricing
Later from Correvio Pharma
- Cardiome Files New Drug Submission Seeking Canadian Approval of intravenous vernakalant
- Cardiome Enters Commercialization Agreement with Chong Kun Dang for BRINAVESS® in South Korea
- Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
- Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
- Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia
Follow Correvio Pharma into a list and get an email when it puts out news.
Follow Correvio Pharma